TL1A-DR3 Signaling Inhibition for TH17-Driven Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The exact mechanism by which TL1A enhances TH1 and TH17 responses in chronic inflammatory processes remains unclear, and existing treatments for conditions like psoriasis, arthritis, and colitis are inadequate.
Innovation Solution
Inhibiting TL1A signaling through the use of inhibitors, such as TL1A antibodies, to target TH17 cell differentiation and reduce inflammatory cytokine production, including IL-17, IL-22, and IL-9, in conditions like inflammatory bowel disease and rheumatoid arthritis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-generated harmful factors
If TL1A signaling is inhibited to reduce TH17 cell differentiation, then inflammatory cytokine production is reduced, but the mechanism remains unclear and treatment effectiveness is limited
Solution Approach 1:
The patent identifies DR3 as an intermediary receptor that mediates TL1A signaling. By targeting DR3 with inhibitors, the patent blocks the signaling pathway between TL1A and downstream TH17 cells, thereby reducing inflammatory cytokine production. This intermediary approach provides a reliable therapeutic mechanism.
Solution Approach 2:
The patent extracts and isolates the critical signaling component (DR3 receptor) from the complex TL1A signaling pathway. By focusing inhibition on this specific intermediary, the patent achieves effective reduction of TH17 differentiation and inflammatory cytokines without affecting other biological processes.
2Object-generated harmful factors
If existing treatments are used for psoriasis, arthritis, and colitis, then some symptom relief is achieved, but the treatments are inadequate and do not target the root mechanism
Solution Approach 1:
The patent extracts the specific signaling mechanism (TL1A-DR3 pathway) from the complex web of inflammatory interactions. By targeting this specific pathway with inhibitors, the treatment achieves precise action against TH17 cell differentiation and inflammatory cytokines, providing effective relief for psoriasis, arthritis, and colitis while maintaining manageable treatment complexity.
Data Source
AI summary
The present invention relates to the finding that TL1A enhances differentiation of TH17 cells, and enhance IL-17 secretion from TH17 cells. In one embodiment, the present invention provides a method of treating an inflammatory disease comprising determining the presence of a TL1A signaling profile, and treating the disease by administering a composition comprising a therapeutically effective dosage of one or more inhibitors of TL1A or TH17 cell differentiation. In another embodiment, the disease is characterized by TH17 differentiation.